Clinical trial data on GLP-1 drugs has consistently shown rapid weight regain after discontinuation — a finding that shaped how both clinicians and patients understood the long-term limitations of these medications. New real-world evidence from Cleveland Clinic complicates that picture significantly.
According to the announcement, a retrospective cohort study of 7,938 adults with overweight or obesity across Ohio and Florida found that stopping injectable GLP-1 medications like semaglutide or tirzepatide does not typically produce the dramatic rebound seen in controlled trials. Published in the journal Diabetes, Obesity and Metabolism, the study tracked patients who discontinued treatment between three and twelve months after starting, then monitored their weight outcomes and subsequent treatment choices over the following year.
The gap between trial results and real-world outcomes appears to come down to patient flexibility. Earlier randomized trials showed patients regaining more than half of their lost weight within a year of stopping semaglutide or tirzepatide. In everyday clinical practice, patients adjust — restarting therapy, switching drugs, or turning to structured lifestyle support rather than simply stopping altogether.
Hamlet Gasoyan, DS, Ph.D., MPH, of Cleveland Clinic‘s Center for Value-Based Care Research, led the study and pointed directly to this behavior as the likely explanation. “Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials,” he said.
The numbers break down differently depending on why patients were taking the drugs in the first place. Those treated for obesity lost an average of 8.4% of body weight before stopping and regained an average of just 0.5% over the following year. Among that group, 55% did gain weight after stopping, while 45% either maintained or continued to lose. Patients treated for type 2 diabetes showed a different pattern — losing an average of 4.4% before discontinuation and then losing an additional 1.3% in the year that followed, with 56% maintaining or improving their weight outcomes.
Within a year of stopping their initial medication, 27% of patients switched to another drug, 20% restarted their original GLP-1 medication, and 14% continued some form of treatment. Prior research by the same team identified cost and insurance coverage as the most common reasons for stopping, followed by side effects. Patients in the diabetes group were more likely to restart treatment, a pattern the study links to more consistent insurance coverage for diabetes-related prescriptions than for obesity.
What this study offers is not a rebuttal of earlier trial findings but a more complete account of what actually happens when patients navigate these decisions outside a controlled setting — with access to alternatives, clinical support, and the ability to course-correct.
Photo by Pixabay
This article is a curated summary based on third-party sources. Source: Read the original article
